

MERIT Announces Launch of New Website

MADISON, WI, UNITED STATES, March 28, 2022 /EINPresswire.com/ -- MERIT CRO, Inc., a global clinical trial endpoint service provider focusing on the ophthalmic, respiratory, and oncology therapeutic areas, today announced the launch of its redesigned website.



The website redesign delivers quick access to not only the high-level information prospective partners and clients typically look for, but also in-depth details regarding MERIT's focused expertise, core services, global solutions, and technology platform. The revamped website provides a comprehensive view of the company's expanded capabilities along with improved functionality that enhances the user experience.

"We are proud to debut the new MERIT website to our pharma, biotech, and CRO partners as well as future clients who are looking to understand all of MERIT's clinical endpoint services," said Yijun Huang, Co-Founder and CEO of MERIT. "We feel the new website reflects the growth of our company, especially as we expand into the therapeutic area of oncology."

Visit the new website at <https://www.meritcro.com/>

ABOUT MERIT

MERIT is a global clinical trial endpoint service provider specializing in the ophthalmology, respiratory, and oncology therapeutic areas. We partner with CROs and pharmaceutical and biotech companies to deliver reliable endpoint services in multi-regional clinical trials. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide.

MERIT's EXCELSIOR™ technology platform increases accuracy and efficiency by providing a suite of advanced endpoint analysis tools designed based on our extensive collaboration with biopharma companies.

MERIT's offices are located in Madison, WI, North Liberty, IA, and in Shanghai, China. We conduct studies across the globe with experience managing clinical sites in 58 countries.

Stacy Sanderson
MERIT

+1 608-284-8810

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/566337370>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.